Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011912
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off AAV in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Equity Offering 30
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Acquisition 32
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc – Key Competitors 33
Audentes Therapeutics Inc – Key Employees 34
Audentes Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 38
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 40
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 45
Nov 10, 2016: Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 31, 2016: Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
Corporate Communications 51
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 51
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 52
Dec 13, 2016: Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors 53
Jan 05, 2016: Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors 54
Other Significant Developments 55
Nov 29, 2016: Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 25
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Expands its Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Files Registration Statement to Raise up to USD86.3 Million in Public Offering of Shares 30
Audentes Therapeutics Raises USD75 Million in IPO 31
Audentes Therapeutics Acquires Cardiogen Sciences 32
Audentes Therapeutics Inc, Key Competitors 33
Audentes Therapeutics Inc, Key Employees 34
Audentes Therapeutics Inc, Subsidiaries 35

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.:企業のM&A・事業提携・投資動向
    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descript …
  • Agile Therapeutics Inc (AGRX):医療機器:M&Aディール及び事業提携情報
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …
  • Kallpa Generacion SA:企業の戦略的SWOT分析
    Kallpa Generacion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Kyochon F&B Co., Ltd.
    Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析2018
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • Epsilon Energy Ltd (EPS):企業の財務・戦略的SWOT分析
    Summary Epsilon Energy Ltd (Epsilon) is an oil and gas company that provides exploration, exploitation and development of oil and gas reserves. The company provides projects such as Marcellus shale in northeast Pennsylvania, Bakken Shale and Midale Dolomite in Saskatchewan, among others. It operates …
  • Tampa Electric Co:企業の戦略的SWOT分析
    Tampa Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Toronto Hydro Corporation:電力:M&Aディール及び事業提携情報
    Summary Toronto Hydro Corporation (Toronto Hydro) is a municipal electricity distribution utility. It holds businesses in electricity distribution and street lighting and expressway lighting services in Toronto. The company owns and operates electricity distribution system, which delivers electricit …
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • TomTec Imaging Systems GmbH-医療機器分野:企業M&A・提携分析
    Summary TomTec Imaging Systems GmbH (TomTec), formerly TomTec Tomographic Technologies GmbH is a medical device company that offers medical imaging and information management solutions. The company's products comprise image-arena platform, tomtec-arena, reporting, web-solution, IT integration, 2D ec …
  • SkylineDx BV:企業の製品パイプライン分析
    Summary SkylineDx BV (SkylineDx) is a developer and commercializer of gene signature-based diagnostic tests for personalized medicine in oncology. The company offers MMprofiler and AMLprofiler molecular diagnostic tests for blood cancers. Its AMLprofiler is a vitro diagnostic test that recognizes ac …
  • Virgin Atlantic Airways Ltd:企業の戦略・SWOT・財務分析
    Virgin Atlantic Airways Ltd - Strategy, SWOT and Corporate Finance Report Summary Virgin Atlantic Airways Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Peregrine Pharmaceuticals Inc (PPHM)-製薬・医療分野:企業M&A・提携分析
    Summary Peregrine Pharmaceuticals Inc (Peregrine) is a biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment and diagnosis of cancer. The company’s products include Bavituximab, PGN650 and Cotara. Its Bavituximab is a monoclonal antibody that binds to a bas …
  • China Non-ferrous Metal Industry’s Foreign Engineering and Construction Co Ltd:企業の戦略・SWOT・財務分析
    China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Adira Energy Ltd (ADENF):石油・ガス:M&Aディール及び事業提携情報
    Summary Adira Energy Ltd (Adira Energy) is an oil and gas company that acquires and explores crude oil and natural gas resource properties. The company undertakes oil and gas projects across Israel. It also holds interest in three offshore petroleum projects in Yitzhak, Gabriella, and Samuel. Adira …
  • Takara Holdings Inc.:企業の戦略・SWOT・財務情報
    Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Societe BIC (BB):企業の財務・戦略的SWOT分析
    Societe BIC (BB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • S-Oil Corporation Inc (010950)-石油・ガス分野:企業M&A・提携分析
    Summary S-Oil Corporation Inc (S-Oil) is a service driven company that operates in the petroleum and petrochemical industry. The company imports and exports crude oil; as well as manufactures and sells oil refining products, petrochemical products and lube products. S-Oil also produces a wide range …
  • CEMEX, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • C.A. Curtze Co. Inc.
    C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report Summary C.A. Curtze Co. Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆